Tag: investigator safety reporting FDA

Pharmacovigilance Obligations in U.S. Clinical Trials

Posted on digi By digi

Pharmacovigilance Obligations in U.S. Clinical Trials Pharmacovigilance Obligations in U.S. Clinical Trials: FDA Requirements and Compliance Strategies Introduction Pharmacovigilance during clinical trials is critical to safeguarding participants and ensuring that the Food and Drug Administration (FDA) has access to timely and reliable safety data. In the United States, pharmacovigilance obligations are defined by 21 CFR…

Read More “Pharmacovigilance Obligations in U.S. Clinical Trials” »

Clinical Trials in USA, Country-Specific Clinical Trials

IND Safety Reporting Requirements in U.S. Clinical Trials

Posted on digi By digi

IND Safety Reporting Requirements in U.S. Clinical Trials Navigating IND Safety Reporting Requirements in U.S. Clinical Trials Introduction Safety reporting is one of the most critical obligations in clinical trials, ensuring that regulators, investigators, and participants are informed of emerging risks. In the United States, the Food and Drug Administration (FDA) has established specific requirements…

Read More “IND Safety Reporting Requirements in U.S. Clinical Trials” »

Clinical Trials in USA, Country-Specific Clinical Trials